Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Belite Bio, Inc
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
July 6, 2026
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
June 12, 2026
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
April 27, 2026
Belite Bio to Participate in Four Upcoming Investor Conferences
April 23, 2026
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
April 21, 2026
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 31, 2026
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
January 27, 2026
←
Previous Page
1
2